Products
Description
ADA (American Diabetes Association) has confirmed that uncontrolled and untreated Postprandial Hyperglycaemia in diabetes is an independent risk factor for progression of atherosclerosis, increased oxidative stress and CVD.
Postprandial Hyperglycaemia is a serious concern not only because of the elevated glucose level but it also exerts various indirect effects on various organs / glands, makes the pancreatic beta cells to secrete large amounts of insulin and would lead to pancreatic beta cell fatigue and / or failure. High levels of PP Glucose also increases the plasma TG (Triglyceride) levels as a considerable part of glucose is stored as TGs in the adipose tissue and other sites. This, in the long term, is strongly linked to obesity and is associated with progression of AGE (Advanced Glycated End product) formation, which markedly develops the triopathies (microvascular complications) associated with diabetes.
Voglibose is an alpha-glucosidase inhibitor; it is an oral anti-diabetic drug used for Type 2 Diabetes mellitus. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. Hence, alpha glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar and decreases the Post Prandial Hyperglycemia in diabetes and thereby reduces the risk of macrovascular complications.
VOLIPHAGE 0.2® / VOLIPHAGE 0.2® TABLETS
(ORAL ANTI-HYPERGLYCEMIC AGENT)
Composition
VOLIPHAGE™ 0.2
Each uncoated tablet contains:
Voglibose ...................................................................... 0.2 mg.
Excipients...................................................................... q.s.
VOLIPHAGE™ 0.3
Voglibose . .................................................................... 0.3 mg.
Excipients ..................................................................... q.s.
ORAL ANTI-HYPERGLYCEMIC DRUGS
ANTI-HYPERLIPIDEMIC DRUGS
ANTI-OBESITY
PAIN MANAGEMENT
ANTI-HYPERURICEMIC DRUGS
VITAMINS/MINERALS
LAXATIVE